Yale Develops New Depression Research Program

2024-11-01 02:33:29 Lifestyle

630

New Haven, CT – (06-14-18): A new research facility developed by Yale University in New Haven seeks to undertake research into neuroscience to develop new diagnosis and better treatments for an array for mental conditions such as depression, mood disorders and other neuropsychiatric issues. Developed under the leadership of Professor Gerard Sanacora, an experienced Ketamine researcher and the head of the program, the program is dedicated to treat depression through breakthroughs in research.

Suicide rate is at its highest than ever before the U.S. with depression afflicting approximately 16 million of the population. Studies indicate a rise in children and teenagers suffering from the debilitating disease. FDA-approved antidepressants available in the market do not suit every patient as many of them do not respond to the medication. Since Prozac that was introduced some thirty years ago, there have been no new antidepressants drugs, expect for a variation of SSRIs and SNRIs. A worryingly large number of individuals do not respond to these medications and get worse with frequent depressive episodes along with suffering side effects from medications.

Scientists are just now beginning to understand that depression is not a monolithic disease and standard treatments are not the solution for every patient.

The research facility comprises a clinical laboratory, a basic science laboratory and research clinic, that seeks to discover the processes that lead to mental abnormalities. ‘Up to one-third of people suffering from depression receive little benefit from the currently available, FDA-approved antidepressants. This is likely to be due to the fact that nearly all of the current medications were developed out of the same pathophysiological model of depression that targets the same monoamine neurotransmitter systems (i.e. serotonin, norepinephrine, and dopamine)’ stated Professor Sanacora, the Medical Director at Yale Depression Research Program.

Understanding the need for better diagnoses and subsequent treatments, the research facility undertakes research into the improvement and prevention of mental disorders. It also seeks to create new approaches for patients who don’t respond to the currently available medications and hopes to have them approved for better clinical treatments.

“Ultimately, we hope these studies will lead to improved treatment outcomes, higher remission rates, and an improved quality of life for those individuals suffering from this disorder,” concluded Professor Sanacora.

The only hope for people suffering from acute neuropsychiatric disorders is to be provided with new treatment strategies, better preventive methods and accurate diagnosis. If the research facility succeeds in its missions, we can expect to see a range of breakthroughs in the world of neurosciences and a better shot at life for those suffering from depression.

About The Company

Based on groundbreaking research, Comfort Zone Trap offers a wealth on resources for people struggling with depression and encourages them to seek treatments for the disease.